Neurotrophic Keratitis — Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
Citation(s)
An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE™ 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)